CorMedix Inc. — Director's Dealing 2013

Mar 22, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2013-03-20

Reporting Person: Duffy Matthew (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-03-20	Stock Option (right to buy)	$0.9	A	100000	Acquired	2023-03-20	Common Stock, $0.001 par value per share (100000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 par value per share	9768	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.68	2022-12-05	Common Stock, $0.001 par value per share (125000)	125000	Direct
Senior Convertible Note (convertible into Common Stock)	$0.35	2013-11-13	Common Stock, $0.001 par value per share (28571)	0	Direct
Warrant (right to purchase Comm Stock)	$0.4	2017-11-13	Common Stock, $0.001 par value per share (25000)	0	Direct
Stock Option (right to buy)	$0.29	2022-01-06	Common Stock, $0.001 par value per share (30000)	0	Direct
Stock Option (right to buy)	$0.28	2021-11-21	Common Stock, $0.001 par value per share (30000)	0	Direct
Warrant	$3.475	2015-03-24	Common Stock, $0.001 par value per share (4884)	0	Direct

Footnotes

F1: These options vest quarterly over two years.

F2: These options vest as follows: fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, if the CE Mark approval is obtained on or before June 30, 2013, and (b) fifty percent (50%) on December 31, 2013.

F3: On November 13, 2012, the reporting person acquired in a private placement $10,000 of (i) 9% Senior Convertible Notes, convertible into shares of the Company's common stock at a conversion price of $0.35 per share; and (ii) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.

F4: These options vest in full on the first anniversary of the date of grant.

F5: The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.

F6: (Right to buy Common Stock, $0.001 par value per share)

F7: The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.